Can rilparencel’s eGFR gains in Group 1 justify accelerated FDA approval for ProKidney in 2025?

ProKidney Corp. is entering a potentially transformative regulatory window after announcing statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial evaluating rilparencel in patients with chronic kidney disease (CKD) and diabetes. The standout finding: a 78% improvement in the eGFR slope for Group 1 patients receiving two rilparencel injections, one in each kidney. With no serious adverse events reported and clear signs of dose-dependent efficacy, the North Carolina-based cellular therapeutics company now turns to a critical FDA Type B meeting this summer, where it hopes to confirm eGFR slope as a surrogate endpoint for accelerated approval.

How does the 78% eGFR slope improvement in REGEN-007 Group 1 align with FDA criteria for surrogate endpoints in 2025?

The FDA has previously signaled that eGFR slope—particularly in progressive diabetic kidney disease—could serve as a suitable surrogate endpoint for accelerated approval if supported by robust clinical data. In the REGEN-007 trial, Group 1 participants experienced an annual eGFR decline of just -1.3 mL/min/1.73m² after rilparencel injections, compared to -5.8 mL/min/1.73m² prior to treatment. This difference of 4.6 mL/min/1.73m² per year was both statistically significant (p<0.001) and deemed clinically meaningful.

Group 1 followed the same dosing schedule used in the ongoing Phase 3 PROACT 1 study, making the REGEN-007 data especially relevant for regulatory forecasting. Notably, 63% of participants in Group 1 met PROACT 1 inclusion criteria, and their outcomes closely mirrored the overall Group 1 performance—strengthening the predictive value of these Phase 2 results. ProKidney is now using this alignment to reinforce its case before the FDA, hoping to finalize eGFR slope as an endpoint that can support a future Biologics License Application (BLA) under the accelerated pathway.

The upcoming Type B meeting will likely hinge on three key factors: the magnitude and statistical strength of the eGFR improvement, the replicability of results across subgroups, and the absence of safety red flags. With rilparencel showing a safety profile comparable to a routine kidney biopsy, ProKidney appears well-positioned heading into this regulatory inflection point.

Why are investors and nephrology experts paying close attention to the surrogate endpoint debate in diabetic CKD?

In a therapeutic space where clinical progression can span years and definitive endpoints like dialysis initiation or transplant are slow to accrue, the acceptance of eGFR slope as a proxy for long-term renal protection could meaningfully accelerate drug development timelines. For patients with diabetic CKD—a population with limited options beyond supportive care—any intervention that can demonstrably slow disease progression is of significant clinical interest.

ProKidney’s rilparencel, a first-in-class autologous cellular therapy, aims to address this unmet need by preserving kidney function before patients reach end-stage renal disease. The regenerative medicine designation already granted by the FDA (RMAT) adds regulatory momentum, but only with a validated surrogate endpoint can ProKidney fully capitalize on its head start in this field.

From a policy perspective, the FDA’s willingness to consider earlier surrogate markers reflects a broader shift toward flexible frameworks in chronic disease trials, particularly where long-term placebo controls are no longer ethical or feasible. If rilparencel is granted accelerated approval based on eGFR slope, it could set a precedent for other cell-based or biologic therapies targeting slow-progressing diseases like CKD.

What milestones could define ProKidney’s regulatory and clinical trajectory through late 2025?

The next major checkpoint will be the FDA Type B meeting scheduled for this summer, where ProKidney seeks to validate its use of eGFR slope as the basis for accelerated approval under the ongoing Phase 3 PROACT 1 trial. A successful outcome would de-risk the regulatory path for rilparencel and potentially allow for earlier market entry if PROACT 1 confirms Phase 2 efficacy.

In parallel, the company plans to submit full REGEN-007 data as a late-breaking abstract for the American Society of Nephrology’s 2025 Kidney Week—further amplifying scientific and clinical awareness. With the Phase 3 trial now targeting high-risk Stage 3b/4 CKD patients with albuminuria, the alignment of trial design, biomarker response, and patient selection could prove decisive.

While long-term outcomes such as dialysis avoidance remain to be validated in Phase 3, ProKidney’s case for accelerated approval now rests on its ability to demonstrate that eGFR slope not only forecasts disease stabilization but also reflects meaningful benefit for patients facing few alternatives. If that threshold is met, rilparencel could become one of the first cell therapies to reshape how kidney failure is prevented—not just managed.